

Harold Longe, MD

ONCOLOGY & HEMATOLOGY

(317) 619-9195

LongeConsulting@Outlook.com

HIGHLIGHTS OF WORK EXPERIENCE

Since 7/15/2009, I have served as a staff Oncologist and Hematologist with Indiana University Health / Central Indiana Cancer Centers / Indiana University Health Physicians. I am a Clinical Assistant Professor of Medicine at the Indiana University School of Medicine. I am Board Certified in Medical Oncology (2009 – present) and Hematology (2011 – present). I also served as a Clinical Instructor in Ambulatory Care and Prevention at Harvard University School of Medicine from January 1998 to June 2005. I have been voted by my peers as an Indianapolis Top Doctor (Indianapolis Monthly) each year since 2016. I was a clinical preceptor for the Boston College Nurse Practitioner Program from July 1996 to June 2001.

EDUCATION

Boston University School of Medicine, Boston Medical Center

07/01/2005 - 06/30/2009

Fellowship in Hematology and Oncology. Lab training. Translational research training.

Woodhull Hospital, Brooklyn, NY

07/01/1993 - 06/30/1996

Internal Medicine Residency.

College of Medicine, University of Ilorin, Nigeria

08/1982 - 05/1988

Medical School. Awards for best performance in Hematology, Pediatrics, and Perinatology.

WORK EXPERIENCE

Oncologist / Hematologist

07/15/2009 – present

Staff Physician, Clinical Assistant Professor of Medicine

Indiana University Health Methodist Hospital / Central Indiana Cancer Centers / Indiana University School of Medicine, Indianapolis, IN

07/01/2003 – 06/30/2005

Staff Physician

Harvard Vanguard Medical Associates, Kenmore Square, Boston, MA

1nternist 07/01/1996 – 06/30/2003

Staff Physician

Brockton Neighborhood Health Center, Brockton, MA

RESEARCH & PRESENTATION EXPERIENCE

Amgen Inc. 2012 – 2014

Multiple presentations as guest speaker/expert presenting new drug, Xgeva

Boston University Cancer Research Center lab of Dr. Gerald Denis

07/01/2005 - 06/30/2009

Completed basic science lab research on novel therapies (using Oligos homologous to telomeres) for Non-Hodgkin's Lymphoma (NHL). Developed mouse model of NHL and worked with various lymphoid malignancy cell lines in-vitro, in transgenic mice and SCID mice.

Boston University Cancer Research Center lab

11/2005, 03/2006, 06/2006, 01/2007, and 06/2007

Research presentations

Boston University Hematology / Oncology Division and Cancer Research Center

2005 - 2009

Research presentations

American Society of Hematology national meeting

12/2005

Telomere-based pre-clinical therapy in a murine model of non-Hodgkin's lymphoma of the diffuse large B cell (DLCL) type

TEACHING EXPERIENCE

Clinical Assistant Professor of Medicine

06/2011 – present

Indiana University School of Medicine, Indianapolis, IN

Clinical Instructor in Ambulator Care and Prevention

01/1998 - 06/2005

Harvard University School of Medicine, Boston, MA

PUBLICATIONS

Tumor Genomic Profiling to Determine Tissue Origin of Cancers of Unknown Primary: A Single Institute Experience With its Utility and Impact on Patient Management.

Saeed OAM, Armutlu A, Cheng L, Longe HO, Saxena R.Appl Immunohistochem Mol Morphol. 2022 Oct 1;30(9):592-599. doi: 10.1097/PAI.000000000001057. Epub 2022 Sep 6.PMID: 36083154

T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.

Saeed OAM, Longe HO, Zhou J.Ann Hematol. 2018 Apr;97(4):721-722. doi: 10.1007/s00277-017-3213-5. Epub 2018 Jan 8.PMID: 29313058

Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential.

Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV.Int J Cancer. 2009 Jan 15;124(2):473-82. doi: 10.1002/ijc.23946.PMID: 19003960

Telomere-based pre-clinical therapy in a murine model of non-Hodgkin's lymphoma of the diffuse large B cell (DLCL) type.

Longe, H., D. V. Faller, and G. V. Denis (2005). Blood 106: 607.

PROFESSIONAL SERVICE

Indiana University Health Division of Hematology and Oncology

2015 – 2017

Thirty-Day Readmission Prevention Committee

OTHER PROFESSIONAL TRAININGS

SEAK Inc. 8/2024

Expert Witness Training